NCT04094519View on ClinicalTrials.gov

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 27, 2020

Primary Completion Date

December 27, 2020

Study Completion Date

December 27, 2020

Conditions
Prostate Cancer
Interventions
DRUG

enzalutamide

oral

DRUG

enzalutamide Placebo

oral

DRUG

digoxin

oral

DRUG

rosuvastatin

oral

Trial Locations (1)

Unknown

Site MD37301, Chisinau

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT04094519 - A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer | Biotech Hunter | Biotech Hunter